These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16631506)

  • 1. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
    Tsimikas S; Willerson JT; Ridker PM
    J Am Coll Cardiol; 2006 Apr; 47(8 Suppl):C19-31. PubMed ID: 16631506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA₂) and lipoprotein(a) (Lp(a)).
    Dallmeier D; Koenig W
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):281-94. PubMed ID: 24840259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
    Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease.
    Tsimikas S
    Am J Cardiol; 2006 Dec; 98(11A):9P-17P. PubMed ID: 17126679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.
    Moriarty PM; Gibson CA
    Am J Cardiol; 2005 May; 95(10):1246-7. PubMed ID: 15878003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease.
    Yeh ET
    Clin Cardiol; 2005 Sep; 28(9):408-12. PubMed ID: 16250263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
    Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
    Am J Cardiol; 2006 Mar; 97(5):640-5. PubMed ID: 16490429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players.
    Virani SS; Pompeii L; Lincoln AE; Dunn RE; Tucker AM; Nambi V; Nasir K; Vogel RA; Boone JL; Roberts AJ; Ballantyne CM
    Atherosclerosis; 2012 Jun; 222(2):551-6. PubMed ID: 22525822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions.
    Iribarren C
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620
    [No Abstract]   [Full Text] [Related]  

  • 17. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
    Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
    N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.